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Long term mortality after a single treatment course with X-rays in
patients treated for ankylosing spondylitis
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lImperial Cancer Research Fund Cancer Epidemiology and Clinical Trials Unit, University of Oxford, Radcliffe Infirmary,
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Summary Mortality up to 1 January 1983 has been studied in 14,106 patients with ankylosing spondylitis
given a single course of X-ray treatment during 1935-54. For neoplasms other than leukaemia or colon
cancer, mortality was 28% greater than that of members of the general population of England and Wales,
and this increase is likely to have been a direct consequence of the treatment. The proportional increase
reached a maximum of 71% between 10.0 and 12.4 years after irradiation and then declined. There was only
a 7% increase in mortality from these tumours more than 25.0 years after irradiation and only for cancer of
the oesophagus was the relative risk significantly raised in this period. Neither the magnitude of the relative
risk, nor its temporal pattern following treatment, were greatly influenced by the age of the patient at first
treatment.
For leukaemia there was a threefold increase in mortality that is also likely to have been due to the
radiotherapy. The relative risk was at its highest between 2.5 and 4.9 years after the treatment and then
declined, but the increase did not disappear completely, and the risk was still nearly twice that of the general
population more than 25.0 years after treatment. There was some evidence that the risks of acute myeloid,
acute lymphatic, and chronic myeloid leukaemia were all increased, but no evidence of any increase in chronic
lymphatic leukaemia. The relative risk appeared to be greatest for acute myeloid leukaemia.
For colon cancer, which is associated with spondylitis through a common association with ulcerative colitis,
mortality was increased by 30%.
For non-neoplastic conditions there was a 51% increase in mortality that was likely to be associated with
the disease itself rather than its treatment. The increase was apparent for a wide range of diseases and was
not confined to diseases that have been associated clinically with ankylosing spondylitis.
Court Brown & Doll identified over 14,000 patients with
ankylosing spondylitis who had been treated with X-
irradiation at some time between 1935 and 1954 at any one of
87 radiotherapy centres in Great Britain and Northern
Ireland. Initial reports analysed mortality in these patients
from leukaemia (Court Brown & Doll, 1957) and other
cancers (Court Brown & Doll, 1965) and related the inci-
dence of leukaemia to the dose received. These analyses
included many patients who had been treated with X-rays
for their spondylitis more than once and it was not clear
whether the increase that continued for many years should
be attributed to the first or subsequent courses. When Smith
& Doll (1978; 1982) reported on the follow-up of the
patients to 1970, they avoided this difficulty by restricting
the analyses to patients who had received only a single
course of treatment. Their analyses showed that, when the
mortality of the spondylitic patients was compared with that
of the general population, the relative risk of leukaemia was
at a maximum 3-5 years after treatment and subsequently
declined. For other cancers of sites judged to be heavily
irradiated, the relative risk was at a maximum 9-11 years
after treatment and then declined to less than one after 24
years. Only a small proportion of patients had been followed
beyond 20 years, however, and the decreasing trend in
relative risk for these other cancers more than 11 years after
treatment was not statistically significant. We have,
therefore, sought to find out how long the increased
mortality from leukaemia and other cancers persisted
following X-ray treatment by extending the follow-up of
patients who received only a single course of treatment by a
further 13 years and have related the increased mortality to
organ dose. We report here only the data for total and
organ specific mortality and have deferred discussion of the
complex relationship with dose to a later report.
Material and methods
Study population andfollow-up
A total of 14,554* patients was included in the study. Four
hundred and forty eight patients were excluded from further
analysis because they had received radiotherapy for their
spondylitis before being entered into the study (405), or they
had received thorium treatment before, or simultaneously
with, their first course of radiotherapy (5), or their date of
birth was unknown (38) (Table I).
Follow-up information about the remaining 14,106
patients was sought from the National Health Service
Central Registers. For persons who could not be found on
the Registers, letters were sent to radiotherapy centres,
general practitioners, or individual patients. All but 171
patients (1.2%) were traced in this way to their death, date
of emigration from the United Kingdom, 1 January 1983, or
18 months after a second treatment course with radiotherapy
or thorium. Re-treated patients were retained in the study
for 18 months after re-treatment because some patients may
have been re-treated for symptoms attributable to cancer
which were misdiagnosed as a recurrence of their spondylitis.
Any solid cancers induced by the re-treatment are unlikely to
have appeared and caused death in this short interval. For
leukaemia, however, the interval between radiation exposure
and resulting death may be less than for solid cancers, and
deaths from this cause occurring after a second treatment
were included only if they occurred within the following 12
months (see below).
By 1 January 1983 just over half the patients had been re-
treated and 346 had emigrated (Table I). A total of 2,983
patients were alive and living in the United Kingdom and
*This number is six less than reported previously (Smith & Doll,
1982). One patient was found to have been included twice, one to
have received the initial radiotherapy for a disease other than
spondylitis, two never to have received radiotherapy, and two
computer records had serial numbers that did not appear on the
original listings.
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Table I Definition of study population: numbers (and percentages) of patients. Re-treated
patients are included for 18 months after re-treatment.
Men Women Total
Total no. of patients 12,160 2,394 14,554
More than 1 treatment
course at entry 351 54 405
Thorium before or with
flrst treatment 4 1 5
Date of birth unknown 33 5 38
Total excluded 388 60 448
Alive
(i) 18 months after 2nd
treatment course or
thorium treatment, or 6,217 (52.8) 1,214 (52.0) 7,431 (52.7)
(ii) on 1 January 1983,
if earlier. 2,482 (21.1) 501 (21.5) 2,983 (21.1)
Deada 2,668 (22.7) 507 (21.7) 3,175 (22.5)
Emigrateda 272 (2.3) 74 (3.2) 346 (2.5)
Lost to follow-upa 133 (1.1) 38 (1.6) 171 (1.2)
Study group 11,772 (100) 2,334 (100) 14,106 (100)
Person-years at risk 152,979 30,770 183,749
Average time in study (yrs)
Re-treated patients 3.56 3.28 3.52
Other patients 23.55 23.92 23.62
aWithin 18 months after 2nd treatment course or thorium treatment, or before 1 January
1983, whichever was the earlier.
3,175 patients had died; that is 81 % more than in the
previous report. For re-treated patients, the average time
spent under observation was 3.52 years and for other
patients 23.62 years.
For all but three of the patients who had died, the causes
of death were obtained from death certificates or drafts of
particulars to be registered. For the remaining three patients,
two of whom had died while temporarily abroad, the cause
of death could not be discovered. For deaths occurring
before the end of 1970, the underlying cause of death was
coded according to the 7th revision of the International
Classification of Diseases, Injury and Causes of Death (ICD)
(World Health Organization, 1957) while later deaths were
coded to the 8th revision (World Health Organization, 1967).
Method of analysis
Person-years at risk were computed by entering each patient
into the study on the first day of his or her first treatment
course and removing him or her eighteen months after re-
treatment, on the date of death, emigration, loss to follow-
up, or on 1 January 1983, whichever was the earliest. If only
the year in which an event took place was known, it was
assumed to have taken place in the middle of the year.
Person-years were calculated separately for males and
females in each five-year age group up to 85 years in the
calendar period 1935-40, in each quinquennium from 1941-5
to 1971-5, and in 1976-82. For each cause of interest the
number of deaths expected was calculated by multiplying the
person-years at risk by the corresponding age- sex- and
period-specific mortality rates for England and Wales.
Mortality rates were taken from the tables published by Case
et al. (1976) and by the Office of Population Censuses and
Surveys (1975), or compiled from the annual reports of the
Registrar General for England and Wales. For leukaemia,
death rates prior to 1968 were compiled using published data
(Court Brown & Doll, 1959) and unpublished data based on
a review of leukaemia death certificates for England and
Wales from 1958 to 1967, made available by Dr L. Kinlen.
For all periods the observed and expected rates were
grouped to make them correspond with groups of causes as
defined under the 7th ICD revision (8th for leukaemia).
The 54 deaths occurring in persons aged 85 years and over
and the number of deaths expected in the corresponding 256
person years at risk were excluded from our analysis for
three reasons: firstly, the diagnostic accuracy of causes of
death on death certificates tends to diminish with increasing
age, particularly in the very old; secondly, the estimation of
expected deaths calculated from national rates for an open-
ended age group is liable to be inappropriate, and thirdly,
the expected number will be materially inflated if, in an age
group with a mortality rate of 25% a year, even a few
patients are assumed erroneously to be alive and in the
United Kingdom when they had actually emigrated or died.
Relative risks were estimated as the ratio of the number of
deaths observed to that expected, and excess risks as the
difference between the observed and expected numbers of
deaths divided by the person-years at risk. Significance tests
were carried out assuming that the observed number of
deaths had a Poisson distribution and that the expected
number was fixed. For testing departures of the relative risk
from one, exact one-sided tests were carried out. Other
significance tests were carried out using the score statistic
(Cox & Hinkley, 1974). For testing for a trend in relative
risk this gave the standard Mantel test for trend, and a two-
sided test was used. For testing equality of two relative risks
it gave the standard binominal test, for testing for a change
in the relative risk standardized by site of cancer or age at
exposure it gave the standard Mantel-Haenszel procedure,
and for testing for homogeneity of several relative risks it
gave the standard x2 statistic. This last test was supple-
mented by examination of the most extreme standardized
departure from the overall mean (Pearson & Hartley, 1976).
We have presented most of our results in terms of relative
rather than excess risks, but in the tables person-years at risk
are included, as well as observed and expected deaths, so
that excess risks can also be calculated.
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Results
Neoplastic disease
In previous reports (Court Brown & Doll, 1965; Smith &
Doll, 1982) neoplastic diseases were divided into four
categories: leukaemia, which was considered separately
because the pattern of occurrence following radiation
differed from that of other cancers in several respects; colon
cancer, which may be associated with spondylitis through the
increased risk of ulcerative colitis suffered by these patients;
cancers of heavily irradiated sites (pharynx, oesophagus,
stomach, pancreas, larynx, lung, ovaries, skin, and bones
excluding jaw and nose; also Hodgkin's disease, other
lymphomas, tumours of spinal chord and nerves, and
tumours of unspecified site), corresponding to organs
thought most likely to have been directly in standard
treatment beams; and cancers of lightly irradiated sites,
corresponding to organs thought unlikely to have been
included directly in radiation beams. Estimates of the mean
organ doses using Monte Carlo techniques have confirmed
that most of the organs previously classed as heavily
irradiated received doses in excess of Gy (100 rad) (Lewis
et al., in preparation). However, many organs previously
classed as lightly irradiated, including liver, kidney, bladder,
and uterus, have also been estimated to have received doses
in excess of 1 Gy (100 rad). The unexpectedly high estimates
for these sites arise partly because some of each organ lay
directly in the radiation beam for several standard treatments
and partly because the estimated dose from scattered radiation
was higher than anticipated. Because of these organ dose
estimates the distinction between heavily and lightly ir-
radiated sites has been abandoned in the present report, and
all neoplasms, other than leukaemia and colon cancer, have
been considered together. The dose estimates indicate that
total body dose in males and females is very similar, and
that patients over the age of 45 when treated received doses
about 10% lower than those treated at younger ages.
Neoplasms other than leukaemia or colon cancer. There was
a 28% increase in neoplasms other than leukaemia or colon
cancer, which was statistically highly significant (Table II;
P<0.001). The relative risk for males was higher than for
females but the difference was not statistically significant
(Table II; x2 (1 df)=0.03, P>0.0). When observed and
expected deaths were examined by time since first treatment
in 2.5 year intervals, the relative risk was high (1.57) in the
first 2.5 years but fell to just over 1.1 in the period 5.0-7.4
years after treatment before rising again to above 1.5
between 10.0 and 17.5 years after exposure (Table III). More
than 17.5 years after treatment the relative risk declined, and
the trend was highly significant (X2 (1 df trend 10.0-12.4
years...,_ >35.0 years)= 12.65; P<0.001). From 25.0 years
after treatment the number of observed deaths was only
slightly greater than the number expected (178 against
166.56) and, for this period, the relative risk was 1.07 with
95% confidence interval 0.92 to 1.24. When the analysis was
repeated for cancers of heavily irradiated sites, as defined in
the previous report (Smith & Doll, 1982), a similar pattern
was obtained.
Some of the tumours presenting soon after treatment may
have caused the symptoms that were incorrectly ascribed to
spondylitis, so that these early observations should be
excluded from any assessment of the effects of the treatment
(Smith & Doll, 1982). The early excess is limited to the first
5 years after treatment, after which the relative risk is, for a
short period, close to 1.0 (1.12 in the period 5.0-7.4 years).
We have, therefore, shown the results for individual cancer
sites separately for the first five years following treatment
(Table IV). In this early period there is little evidence of
variation between the relative risks for the individual sites,
apart from the very high figure for spinal cord tumours
which often present with pain in the back (X2 (22df)=288.2,
P<0.001 for all neoplasms other than leukaemia or colon
cancer; x2 (21 df)= 19.03, P>0.10 excluding spinal cord
tumours and P>0.10 for most extreme departure from
overall mean). It is notable, however, that the relative risks
for cancers of the pancreas and prostate are the second and
third highest (and significantly increased) and that these
diseases are also particularly prone to be confused with
ankylosing spondylitis since they also frequently present with
pain in the back due to direct spread or spinal secondaries.
In the period 5.0 or more years following exposure there is
evidence of a higher relative risk for oesophagus than for other
sites, but the variation among the remaining individual relative
risks was not statistically significant (X2 (22 df) = 29.47,
P>0.10, but P<0.05 for departure of oesophagus from
overall mean). The high relative risk for spinal cord tumours
(4.72) was due to only 1 death. Among the individual sites
there were significant increases for cancers of the oesophagus
(28 observed, 12.73 expected; P<0.001), lung (224 observed,
184.49 expected; P<0.01), bones, excluding jaw and nose
(4 observed, 1.36 expected; P<0.05), other lymphomas (16
observed, 7.14 expected; P<0.01), breast (26 observed, 16.07
expected; P <0.05), and central nervous sytem (CNS)
tumours other than the spinal cord (22 observed, 14.03
expected; P< 0.05). The relationship with dose will be
reported later (Darby et al., in preparation), but we note
now that the estimates of the mean doses to the oesophagus
and main bronchi were substantial, of the order of 5 Gy
(500 rad), and the skeletal dose was of the order of 3 Gy
(300 rad). Similarly, although a dose to the lymph nodes
has not been estimated, the mediastinal lymph nodes were
directly in the beam for many patients and thus received a
high dose. The dose to the breast has not been estimated
directly but assuming that it is likely to be about one quarter
of the lung dose leads to an approximate figure of 0.5 Gy
(50 rad). The relative risk observed is perhaps surprisingly
high in view of the lack of increase in women who were
irradiated in middle age in Hiroshima and Nagasaki and
Table II Observed and expected deaths at ages less than 85 years for males and females by major groups of disease.
Re-treated patients are included for 18 months after re-treatment.
Males Females Total
Observed Expected OIE Observed Expected OIE Observed Expected OIE
All causes 2,635" 1,828.27 1.44 486b 305.14 1.59 3,121b 2,133.41 1.46
All neoplasms 623b 464.86 1.34 104a 82.35 1.26 727b 547.21 1.33
Leukaemiac 36b 10.50 3.43 3 1.79 1.68 39b 12.29 3.17
Colon cancer 38a 28.16 1.35 9 7.96 1.13 47a 36.11 1.30
Other neoplasms 548b 426.16 1.29 gla 72.60 1.25 639b 498.76 1.28
All other causes' 2,012b 1,363.42 1.48 382b 222.78 1.71 2,394b 1,586.20 1.51
ap< 0.5; bP<0.001; cFor leukaemia re-treated patients are included for only 12 months after re-treatment. There
were 2 leukaemia deaths observed, and 0.05 expected in the period 12-18 months following re-treatment; dIncludes 3
deaths for which the cause was not known.
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Table IV Observed and expected deaths at age less than 85 years from neoplasms other than leukaemia or colon cancer by site of
cancer and time since first treatment. Re-treated patients are included for 18 months after re-treatment.
Time since first treatment (years)
< 5.0 5.0-24.9 . 25.0 Total . 5.0
Sited 0 E OIE 0 E O/E 0 E OIE 0 E OIE
Cancer of mouth 0 0.26 0.00 2 1.19 1.68 1 0.71 1.41 3 1.90 1.58
Cancer of pharynx 0 0.37 0.00 3 1.69 1.77 1 0.88 1.14 4 2.57 1.56
Cancer of oesophagus 1 1.19 0.84 15b 7.33 2.05 13b 5.40 2.41 28C 12.73 2.20
Cancer of stomach 9 8.88 1.01 44 36.54 1.20 11 17.80 0.62 55 54.34 1.01
Cancer of rectum 3 3.21 0.94 16 14.04 1.14 8 8.34 0.96 24 22.38 1.07
Cancer of liver 2 0.74 2.71 2 3.45 0.58 4 1.99 2.01 6 5.44 1.10
Cancer of pancreas 6a 1.85 3.24 14 12.37 1.13 7 8.17 0.86 21 20.54 1.02
Cancer of larynx 2 0.70 2.84 4 2.92 1.37 3 1.62 1.85 7 4.53 1.54
Cancer of lung 20 16.38 1.22 155C 113.08 1.37 69 71.41 0.97 224b 184.49 1.21
Cancer of breast 4 2.53 1.58 21b 11.15 1.88 5 4.92 1.02 26a 16.07 1.62
Cancer of uterus 0 1.24 0.00 5 4.35 1.15 1 1.54 0.65 6 5.89 1.02
Cancer of ovaries 1 0.86 1.17 4 3.75 1.07 1 1.62 0.62 5 5.37 0.93
Cancer of prostate 4a 1.31 3.04 12 9.70 1.24 9 8.45 1.07 21 18.15 1.16
Cancer of kidney 1 0.90 1.11 8 4.98 1.61 4 2.94 1.36 12 7.92 1.52
Cancer of bladder 3 1.53 1.96 9 9.89 0.91 11 6.79 1.62 20 16.67 1.20
Cancer of skin 0 0.54 0.00 3 2.44 1.23 2 1.32 1.52 5 3.76 1.33
Spinal cord tumours 4c 0.04 90.61 1 0.15 6.77 0 0.06 0.00 1 0.21 4.72
CNS tumours (excl.
spinal cord) 2 2.98 0.67 16a 10.01 1.60 6 4.02 1.49 22a 14.03 1.57
Cancer of bones (excl.
nose and jaw) 1 0.53 1.88 3 1.02 2.95 1 0.34 2.96 4a 1.36 2.95
Hodgkin's disease 3 1.24 2.42 5 3.02 1.66 0 0.78 0.00 5 3.80 1.32
Other lymphomas 2 0.99 2.03 13c 4.49 2.89 3 2.65 1.13 16b 7.14 2.24
Multiple myeloma 0 0.33 0.00 4 2.63 1.52 4 2.03 1.97 8 4.66 1.72
Other neoplasms 8 4.20 1.90 26 19.20 1.35 14 12.78 1.10 40 32.00 1.25
Total 76b 52.80 1.44 385C 279.39 1.38 178 166.56 1.07 563C 445.95 1.26
ap<0.o5; bp<0.01; CP<0.001; dICD-7 codes are as follows: mouth (143, 144, 145.0); pharynx (145-148 excl. 145.0); oesophagus
(150); stomach (151); rectum (154); liver (155, 156, excl. 155.1); pancreas (157); larynx (161, 162.0 pt. 165); lung (162.1, 162.2, 163);
breast (170); uterus (171-174); ovaries (175); prostate (177); kidney (180, 195.0); bladder (181); skin (190, 191); spinal cord
tumours (193.1, pt. 223, pt. 237); CNS tumours excl. spinal cord (193 excl. 193.1, pt. 223, pt. 237); bones excl. jaw, nose (196 excl.
196.0, 196.1); Hodgkin's disease (201); other lymphomas (200, 202, 205); multiple myeloma (203); other (140-239 less those
otherwise specified).
who received comparable doses (kerma doses of between 0.1
and 1.00 Gy (10 and 100 rad)) (Tokunaga et al., 1984). It is
possible however that women patients who were irradiated
on account of their spondylitis may have tended to remain
nulliparous or delay their first pregnancy compared with
other women, which would cause them to have a higher risk
of breast cancer than the national figures suggest (MacMahon
et al., 1973).
Twenty-one of the 22 observed deaths from tumours of
the CNS other than the spinal cord occurred in the brain.
The mean brain dose is estimated to be relatively low, under
0.15 Gy (15 rad). One possible explanation of the observed
increase in deaths attributed to brain tumours is that brain
secondaries from a primary growth in the lung are
commonly misdiagnosed as primary brain tumours. Thus the
excess of lung cancer and the misclassification of brain
metastases from lung cancer may have generated an
apparent increase in brain cancer.
In Table IV results for the period more than 25.0 years
after treatment are shown separately from those for the
period 5.0-24.9 years. In the later period, there was a
statistically significantly raised relative risk only for cancer of
the oesophagus, and the variation between the remaining
sites was not significant (X2(22df)=23.48, P>0.10, but
P< 0.05 for departure of oesophagus from overall mean).
The relative risk for all neoplasms, other than leukaemia
and colon cancer, during the period 5.0-24.9 years after treat-
ment (1.38) is significantly higher than that for later periods
(1.07) and the result is unchanged after standardization
for site of origin of the tumour ( I2(1df)= 7.67, P<0.01
unstandardized; x2 (1 df)=7.72, P<0.01 standardized).
Approximately 40% of the deaths in each time period were
from lung cancer. If lung cancer is excluded, the pattern
among the remaining sites is broadly similar, although the
relative risk in the period 5.0-24.9 years after treatment
(1.38) is not significantly different from that for 25.0 years
onwards (l.15) (X2 (l df)=2.45, P>0.10).
In Table V the numbers of observed and expected deaths
from neoplasms other than leukaemia and colon cancer in
the periods 5.0 to 24.9 and more than 25.0 years after first
treatment have been divided into five groups according to
the age of the patient when first treated. In all five age
groups the relative risk more than 25.0 years after first treat-
ment is lower than that in the earlier period, and in no age
group is the relative risk significantly increased in the later
period. After standardization for age at first treatment, the
relative risk in the period 5.0 to 24.9 years after first treat-
ment remains significantly different from that for the period
more than 25.0 years after first treatment (X2 (1 df) = 8.94,
P <0.01). In the period 5.0 to 24.9 years after treatment
there is some tendency for the relative risk to be higher in
patients treated at younger ages, but the trend with age is not
quite significant (X2 (1 df)= 3.38, 0.0>P>0.05).
In Table VI the numbers of observed and expected deaths
from neoplasms other than leukaemia and colon cancer in
the periods 5.0 to 24.9 and more than 25.0 years after
treatment are shown separately for males and females. For
neither group is the relative risk in the later time period
significantly increased. The relative risk in the period more
than 25.0 years after first treatment remains significantly
different from that for the earlier period after standardiza-
tion for sex (x2 (1 df)= 7.72, P< 0.01).
To investigate further whether the apparent decrease in
relative risk with time since exposure for neoplasms other
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Table V Observed and expected deaths from neoplasms other than leukaemia or colon cancer at ages less than 85 years
by time since first treatment and age at first treatment. Re-treated patients are included for 18 months after re-treatment.
Time since first treatment (years)
5.0-24.9 >25.0 Total >5.0
Age at first Years Years Years
treatment 0 E O/E at risk 0 E O/E at risk 0 E O/E at risk
<25 13a 6.59 1.97 16,519 13 12.32 1.06 5,597 26 18.90 1.38 22,117
25-34 73c 47.19 1.55 40,294 61 62.50 0.98 12,181 l34- 109.69 1.22 52,475
35-44 1350 98.37 1.37 30,432 75 68.06 1.10 6,919 210C 166.42 1.26 37,351
45-54 114b 84.15 1.35 12,870 28 22.40 1.25 1,602 1420 106.56 1.33 14,472
.55 50 43.09 1.16 4,131 1 1.28 0.78 71 51 44.38 1.15 4,201
Total 385C 279.39 1.38 104,246 178 166.56 1.07 26,370 563C 445.95 1.26 130,616
ap<0oo5; bp<0.01; Cp<0.001.
Table VI Observed and expected deaths from neoplasms other than leukaemia or colon cancer at ages less than 85 years
in males and females by time since first treatment. Re-treated patients are included for 18 months after re-treatment.
Time since first treatment (years)
5.0-24.9 . 25.0 Total . 5.0
Years Years Years
0 E O/E at risk 0 E OIE at risk 0 E O/E at risk
Males 331c 236.97 1.40 86,713 154 145.69 1.06 21,870 485C 382.66 1.27 108,583
Females 54a 42.43 1.27 17,533 24 20.87 1.15 4,500 78a 63.29 1.23 22,033
Total 385C 279.40 1.38 104,246 178 166.56 1.07 26,370 563C 445.95 1.26 130,616
ap<0 05; cP<0.001.
than leukaemia and colon cancer in the later part of the
follow-up period could be due to confounding by age at
exposure or sex, a Poisson regression modelling procedure
(Darby et al., 1985) was carried out in which the pattern of
relative risk with time since treatment in 2.5 year intervals
was examined after allowing simultaneously for the effect of
age at first treatment and sex. No evidence of confounding
was revealed.
Cancer of the colon. The relative risk for cancer of the colon
was 1.30 (Table II, P<0.05). There was some tendency
for the relative risk to decrease with increasing time since first
treatment, but the trend was not quite significant (Table III;
x2 (1 df trend 5.0-7.4 years, . . ..,35.0 years)= 3.42,
0.10>P>0.05). The relative risk was highest in the period
5.0-7.4 years after treatment with 5 deaths observed and
1.82 expected. During the period 5.0-24.9 years after treat-
ment there were 28 deaths compared with 19.93 expected.
This 40% increase was not quite significantly different from 0
(0.10>P>0.05) nor was it significantly different from the
increase observed for all cancers other than leukaemia or
colon cancer during this time period (X2 (I df)=0.00,
P>0.10).
Leukaemia. In healthy individuals receiving a single
exposure to radiation, it seems unlikely, from consideration
of the rate at which cells proliferate, that any death from
radiation-induced cancer would occur within two years, and
even in spondylitics in whom cell kinetics may be modified
because they receive a series of fractional doses and are often
anaemic before treatment, it seems very unlikely that it
would occur within a year. In fact, after the three patients
reported previously who died from leukaemia within four
months of treatment and whose disease is thought to have
been present at treatment (Smith & Doll, 1982), the next
shortest latent interval occurred 15 months after a first course
of treatment. It is impossible to be sure that this death
was not due to irradiation and we therefore recalculated
the person-years at risk including re-treated patients only for
12 months after re-treatment and counted observed deaths
only for the same period. With this restriction there were 39
deaths from leukaemia compared with 12.29 expected from
national mortality rates for England and Wales (Table II).
This increase, which is statistically highly significant,
(P<0.001), was greater, but not significantly so, in men than
in women (X2 (1 df)=0.98, P>0.10). The relative risk was
highest 2.5-4.9 years after treatment (Table III) and there-
after declined (x2 (1 df trend 2.5-4.9 years, . .. . 35.0 years) =
12.25; P<0.001). More than 15.0 years after treatment the
relative risk was 1.87, and was still significantly increased
(P<0.05). Its value during the period 15.0 to 24.9 years after
treatment was similar to, but slightly less than, that for the
period more than 25.0 years after treatment (1.80 against
1.94). Thus there is no evidence from these data that the
increased risk disappeared completely, nor that it was
changing materially more than 15.0 years after exposure.
There was no significant trend with age at exposure in the
relative risk of leukaemia one or more years following
exposure (Table VII. x2 (1 df trend)=0.66; P>0.10), nor was
there any when the periods 1.0-14.9 years after exposure and
more than 15.0 years after exposure were considered
separately (1.0-14.9 years: x2 (1 df trend)=0.00, P>0.10;
.15.0 years: x2 (ldf trend)=0.32, P>0.10). Within each
age at first treatment group the relative risk more than 15.0
years after treatment was less than that in the period 1.0-
14.9 years after treatment. Poisson regression modelling of
the relative risk allowing simultaneously for time since
treatment, age at treatment, and sex did not reveal any new
features of the data.
Of the 36 deaths certified as due to leukaemia and
occurring one or more years after first treatment, it was
possible to obtain case notes for 32. For one of these,
certified as due to acute myeloid leukaemia, the notes
suggested a diagnosis of myelodysplasia. For 16 deaths,
including 12 of the 14 certified as due to acute myeloid
leukaemia, the case notes confirmed the type of leukaemia as
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Table VII Observed and expected deaths from leukaemia at ages less than 85 years by age at first treatment.
Re-treated patients are included for 12 months after re-treatment.
Time since first treatment (years)
1.0-14.9 . 15.0 Total . 1.0
Age at first Years Years Years
treatment (years) 0 E OIE at risk 0 E O/E at risk 0 E OIE at risk
<25 1 0.34 2.98 14,479 0 0.58 0.00 13,161 1 0.91 1.10 27,640
25-34 5b 1.00 4.98 34,446 5 2.26 2.21 30,503 10j 3.26 3.06 64,949
35-44 8c 1.20 6.66 27,224 4 2.77 1.44 20,061 12C 3.97 3.02 47,285
45-54 4- 1.03 3.90 13,020 5a 1.50 3.34 6,396 gb 2.52 3.57 19,416
.55 4a 0.83 4.85 5,325 0 0.39 0.00 1,148 4a 1.22 3.28 6,472
Total 22C 4.39 5.01 94,494 14a 7.50 1.87 71,269 36G 11.89 3.03 165,763
ap<0 05; bp<0.01; cp<0.001.
given on the death certificate. For a further 8 the type could
be determined more precisely from the case notes than from
the death certificate, but there was no conflict between the
two. For 3 deaths the type of leukaemia was described less
precisely in the case notes than on the death certificate, but
there was no direct conflict. For the remaining 4 deaths
(with certified types, acute lymphatic (1), chronic myeloid
(1), and unspecified lymphatic (2)) the type of Ieukaemia
described on the death certificate was contradicted by the
case note information, and in 3 of these the case notes led to
a diagnosis of acute myeloid leukaemia.
Review of the case notes and biopsy specimens of 5 of the
7 patients whose cause of death was given on the death
certificate as aplastic anaemia showed that death was
actually due to leukaemia in a further 2 patients (who died
at 2 and 4 years after first treatment for spondylitis) (Court
Brown & Doll, 1957; Smith & Doll, 1982). Leukaemia was
also recorded on the death certificate, but not as the
underlying cause of death, for 5 other patients (who died at
5, 6, 10, 12, and 32 years after first treatment) (Smith &
Doll, 1982). No data for the study period as a whole are
available for deaths in England and Wales with leukaemia
mentioned on the death certificate but not as the underlying
cause, nor is there information on the number of deaths from
leukaemia that were certified as due to aplastic anaemia, or
the number of deaths certified as due to leukaemia when
leukaemia was not, in fact, the cause. We therefore assumed
that the ratio of the number of such deaths to the number of
deaths for which leukaemia was certified as the underlying
cause was the same as we observed in the study series. To
estimate the expected number of deaths with leukaemia
mentioned on the death certificate we multiplied the expected
number of deaths certified as due to leukaemia by 45/39 (see
Table III). This procedure could not alter the overall
estimate of relative risk from that given by the analysis
based on leukaemia as an underlying cause only, but it could
alter the estimate at different periods since treatment and, in
fact, it increased the relative risk in the period between 1.0
and 14.9 years after treatment slightly from 5.01 to 5.53,
with corresponding decreases earlier and later.
Observed and expected deaths one or more years after first
treatment by type of leukaemia as recorded on the death
certificate are shown in Table VIII. These results are difficult
to interpret as the type was incompletely specified for one
third of the observed deaths and for one fifth of those
expected. Nearly half the deaths were certified as due to
acute myeloid leukaemia. This is the specified type with the
highest relative risk and the only one for which a significant
increase was recorded overall (P<0.001), although there was
a significant increase in deaths from chronic myeloid
leukaemia in the period 1.0-14.9 years after treatment
(P<0.05). Only two deaths were certified as due to chronic
lymphatic leukaemia, and this was less than the number
expected (2.38). For all types other than chronic lymphatic
leukaemia, unspecified lymphatic leukaemia and unspecified
chronic leukaemia, the relative risk in the period 1.0-14.9
years after first treatment course was greater than later,
although for acute myeloid leukaemia the increase continued
Table VIII Observed and expected deaths from leukaemia at ages less than 85 years by
type of leukaemia as recorded on the death certificate. Re-treated patients are included
for 12 months following re-treatment.
Time since first treatment (years)
1.0-14.9 >15.0 Total >1.0
Type ofd
leukaemia 0 E OIE 0 E OIE 0 E OIE
Acute myeloid 7c 1.42 4.93 10c 2.92 3.42 17c 4.34 3.91
Acute lymphatic 1 0.46 2.18 1 0.47 2.14 2 0.93 2.16
Chronic myeloid 3a 0.65 4.61 0 1.40 0.00 3 2.05 1.46
Chronic lymphatic 0 0.54 0.00 2 1.84 1.09 2 2.38 0.84
Unspecified acute 2 0.39 5.07 0 0.39 0.00 2 0.79 2.54
Unspecified chronic 0 0.01 0.00 0 0.03 0.00 0 0.04 0.00
Unspecified myeloid 4b 0.51 7.88 0 0.20 0.00 4b 0.71 5.65
Unspecified lymphatic 2a 0.28 7.08 1 0.09 10.77 3b 0.38 8.00
Unspecified leukaemia 3c 0.12 24.62 0 0.16 0.00 3b 0.28 10.79
All types 22c 4.39 5.01 14a 7.50 1.87 36b 11.89 3.03
ap< 0.5; bP<0.01; 'P<0.001; 'ICD-8 codes are as follows: acute myeloid (205.0,
206.0, 207.2); acute lymphatic (204.0); chronic myeloid (205.1, 206.1); chronic lymphatic
(204.1); unspecified acute (207.0); unspecified chronic (207.1); unspecified myeloid (205.9,
206.9); unspecified lymphatic (204.9); unspecified leukaemia (207.9).
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to be statistically significant after 15 years (10 observed, 2.92
expected; P<0.001). The two deaths from chronic lymphatic
leukaemia occurred 26 and 31 years after treatment, but even
in the period more than 15 years after treatment they are
only fractionally more than the number expected (1.84).
Observed and expected deaths more than one year after first
treatment by certified type of leukaemia and age at first
treatment are shown in Table IX. For deaths certified as due
to acute myeloid leukaemia the relative risk increased with
increasing age at exposure. The number of deaths was small,
however, and the trend was not quite statistically significant
(X2 (1 df)= 2.73; 0.10>P>0.05). There is also a suggestion
of a trend in relative risk with age at exposure for the 4
deaths certified as due to unspecified myeloid leukaemia, 2
of which were confirmed as acute myeloid leukaemia from
the case notes.
Diseases other than neoplasms
There was a 51% increase in deaths from diseases other than
neoplasms (Table II; P<0.001) and the relative risk for
females was higher than that for males (x2 (ldf)=7.09,
P<0.01). The relative risk generally declined with increasing
time since irradiation from 1.88 in the first five years to 1.20
more than 30 years after treatment (Table III; x2 (1 df trend
<2.5 years, . ...35.0 years)=40.70, P<0.001). More than
25.0 years after treatment there were 657 deaths compared
with 493.85 expected. This 33% increase was statistically
highly significant (P<0.001). Relative risks by age at first
treatment were: <25 years, 2.09; 25-34 years, 1.56; 35-44
years, 1.51; 45-54 years, 1.51; and _55 years, 1.32. This
decline in relative risk with age at first treatment was
statistically highly significant (X2 (1 df trend) = 14.14,
P<0.001).
Following previous reports (Court Brown & Doll, 1965;
Smith & Doll, 1982), the causes of death have been grouped
into 4 classes (Table X). Class A consists of ankylosing
spondylitis and other musculo-skeletal disorders, some of
which might give rise to diagnostic confusion with spondy-
litis. A wider grouping of these diseases had to be considered
than previously, due to changes from the 7th to the 9th
revision of the ICD, which was used for the national rates in
the last few years of follow-up. Class B consists of diseases
that are clinically associated with ankylosing spondylitis
(Hickling & Wright, 1983). No death was certified as due to
amyloid disease, which is known to be a complication of
spondylitis, although it was mentioned on 10 death certifi-
cates, and 57 deaths were attributed to nephritis (which is
commonly due to unrecognized amyloid disease in spondy-
litics) against 18.42 expected. As in the earlier follow-up of
this group, the numbers of deaths from every cause in
Classes A and B (apart from amyloid disease) were
significantly greater than expected (P<0.001 for each group
except non-rheumatic chronic endocarditis, for which
P<0.01). As expected, the largest proportionate increases
were for ankylosing spondylitis, other musculo-skeletal
disorders, and ulcerative colitis. For all diseases in Class A
combined the ratio of observed to expected deaths was
similar in men and women, but when ankylosing spondylitis
was considered on its own, the ratio for women was
significantly greater than that for men (X2 (1 df)=6.95,
P<0.01). For each of the diseases in Class B the ratios took
similar values in the two sexes, and the differences were not
statistically significant (P>0.10 in each group).
Class C includes neoplasms and aplastic anaemia. The
former have been commented on previously. The latter was
the certified cause of 7 deaths, whereas less than one was
expected (0.96). No further information beyond that given
on the death certificates could be obtained for two patients
who died respectively 18 and 20 years after exposure. Review
of the notes and marrow biopsy specimens showed that two
cases would have been better described as aleukaemic
leukaemia (cases 32 and 41) (Court Brown & Doll, 1957)
and that one (case 44) (Court Brown & Doll, 1957), which
presented about two weeks after exposure, could be regarded
as aplastic anaemia induced by treatment. Marrow specimens
could not be obtained for either of the two remaining cases,
but the information in the hospital notes suggested that
alternative diagnoses would have been preferred (i.e.
thrombocytopenia developing in a woman aged 48, 26 years
after exposure and causing death 7 years later and
macrocytic anaemia or possibly myelodysplasia presenting in
a man aged 70, 37 years after exposure, causing death within
a week). On this evidence, there does not seem to be any
justification for believing that aplastic anaemia is liable to be
a long term effect of irradiation, although conditions liable
to be confused with it may well be.
Class D consists of all other causes of death, for which it
was originally thought that mortality might be close to
normal among patients with spondylitis (Court Brown &
Doll, 1965) apart from a few extra deaths due to spinal
injury. Previous studies (Court Brown & Doll, 1965; Smith
& Doll, 1982), however, have reported an increase in all
disease groups in this class, and this is confirmed by the
present data based on longer follow-up (Table X). The
proportionate increases for each of the individual diseases
considered were less than for any of the diseases in Class B,
other than amyloid disease. For all diseases in Class D
combined, the ratio of observed to expected deaths was
greater for women than for men (X2 (1 df)= 7.00, P<0.0I),
but only for other circulatory disease was the difference
statistically significant (X2 (1 df ) = 4.76, P < 0.05).
Table IX Observed and expected deaths from leukaemia occurring more than one year after first treatment at ages less than 85 years by age at
first treatment and type of leukaemia a, recorded on the death certificate. Re-treated patients are included for 12 months following treatment.
Age at first treatment (years)
<25 25-34 35-44 45-54 .55 All ages
Type of
leukaemia 0 E OIE 0 E OIE 0 E OIE 0 E OIE 0 E OIE 0 E OIE
Acute myeloid 0 0.41 0.00 4 1.37 2.91 7 1.47 4.76 4 0.80 5.00 2 0.29 6.88 17 4.34 3.91
Acute lymphatic 0 0.11 0.00 1 0.28 3.62 0 0.28 0.00 1 0.18 5.63 0 0.09 0.00 2 0.93 2.16
Chronic myeloid 0 0.17 0.00 0 0.60 0.00 2 0.68 2.94 1 0.42 2.40 0 0.19 0.00 3 2.05 1.46
Chronic lymphatic 0 0.07 0.00 2 0.49 4.06 0 0.86 0.00 0 0.63 0.00 0 0.33 0.00 2 2.38 0.84
Unspec. acute 0 0.08 0.00 0 0.23 0.00 1 0.25 4.01 1 0.15 6.62 0 0.07 0.00 2 0.79 2.54
Unspec. chronic 0 0.00 0.00 0 0.01 0.00 0 0.01 0.00 0 0.01 0.00 0 0.01 0.00 0 0.04 0.00
Unspec. myeloid 0 0.04 0.00 0 0.16 0.00 1 0.23 4.35 1 0.16 6.08 2 0.11 17.81 4 0.71 5.65
Unspec. lymphatic 1 0.02 52.08 1 0.06 16.95 0 0.10 0.00 1 0.10 9.72 0 0.10 0.00 3 0.38 8.00
Unspec. leukaemia 0 0.02 0.00 2 0.06 31.90 1 0.09 10.88 0 0.07 0.00 0 0.04 0.00 3 0.28 10.79
All types 1 0.91 1.10 10 3.26 3.06 12 3.97 3.02 9 2.52 3.57 4 1.22 3.28 36 11.89 3.03
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Table X: Observed and expected deaths at ages less than 85 years for males and females from causes other than neoplasms.
Males Females Total
Cause of deathd Observed Expected OIE Observed Expected O/E Observed Expected O/E
Class A
Ankylosing spondylitis 81c 0.24 340.81 9c 0.01 950.34 90C 0.25 364.16
Other musculo-skeletal disorders 44c 5.82 7.56 14C 1.22 11.48 58c 7.04 8.24
Total 125c 6.06 20.62 23c 1.23 18.68 148c 7.29 20.29
Class B
Ulcerative colitis 16c 1.33 12.07 6c 0.39 15.28 22c 1.72 12.80
Non-rheumatic chronic endocarditis 18b 8.63 2.09 2 1.47 1.36 20b 10.10 1.98
Amyloid disease 0 0.40 0.00 0 0.06 0.00 0 0.45 0.00
Nephritis 48c 15.69 3.06 gb 2.73 3.30 57c 18.42 3.09
Pulmonary tuberculosis 104C 30.97 3.36 8a 3.35 2.39 112C 34.31 3.26
Pneumonia j37c 75.06 1.83 35c 16.45 2.13 172c 91.51 1.88
Other respiratory disease
(incl. apical fibrosis) 55C 30.15 1.82 ga 3.53 2.55 64c 33.68 1.90
Total 378c 162.23 2.33 69c 27.98 2.47 447c 190.19 2.35
Class C
All neoplasms 623c 464.86 1.34 104a 82.35 1.26 727c 547.21 1.33
Aplastic anaemia 6c 0.77 7.84 1 0.19 5.16 7c 0.96 7.30
Class D
Cerebrovascular disease 176 157.09 1.12 55 44.79 1.23 231a 201.88 1.14
Other circulatory disease 843c 695.10 1.21 147c 99.35 1.48 990C 794.45 1.25
Bronchitis 169c 123.32 1.37 9 9.23 0.97 178C 132.55 1.34
Peptic ulcer 26 20.66 1.26 6a 1.90 3.15 32a 22.56 1.42
Other gastro-intestinal disease 49c 26.23 1.87 12a 6.52 1.84 61c 32.75 1.86
Violence 108a 86.18 1.25 19a 10.46 1.82 127b 96.65 1.31
All other causes 132c 85.78 1.54 41c 21.13 1.94 173c 106.92 1.62
Total 1,503c 1,194.36 1.26 289c 193.38 1.49 1,792c 1,387.76 1.29
Cause unknown 2 1 3
ap <0.05; bp<0.01; CP<0.001; dICD-7 codes are as follows: Class A: ankylosing spondylitis (722.1); other musculoskeletal disorders
(rest of 720-749). Class B: ulcerative colitis (572.2); chronic endocarditis (421); amyloid disease (289.1); nephritis (590-594); pulmonary
tuberculosis (001-008); pneumonia (490-493); other respiratory disease (rest of 470-527). Class C: all neoplasms (140-239); aplastic
anaemia (292.4). Class D: cerebrovascular disease (330-334); other circulatory disease (rest of 400-468); bronchitis (500-502, 526); peptic
ulcer (540-542); other gastrointestinal disease (rest of 530-587); violence (800-999).
Table XI: Observed and expected deaths from all causes except neoplasms at age less than 85 years for males and females by age at observation
and calendar period. Re-treated patients are included for 18 months after re-treatment.
Age at observation
Calendar
period < 25 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75- 80-84
Up to 1 Jan. 1978
Observed 13 47 57 75 123 176 238 305 309 247 172 133 74
Expected 8.69 15.50 22.60 34.52 55.47 91.32 137.08 176.33 203.21 193.13 157.44 104.21 56.81
O/E 1.50 3.03 2.52 2.17 2.22 1.93 1.74 1.73 1.52 1.28 1.09 1.28 1.30
1 Jan. 1978 to 1 Jan. 1983
Observed 0 0 0 0 1 2 19 38 70 85 101 73 36
Expected 0 0 0 0 0.31 3.04 13.68 33.96 50.68 74.28 73.84 56.11 23.98
O/E - 3.23 0.66 1.39 1.12 1.38 1.14 1.37 1.30 1.50
Total
Observed 13 47 57 75 124 178 257 343 379 332 273 206 110
Expected 8.69 15.50 22.60 34.53 55.78 94.36 150.76 210.29 253.89 267.41 231.28 160.32 80.79
O/E 1.50 3.03 2.52 2.17 2.22 1.89 1.70 1.63 1.49 1.24 1.18 1.28 1.36
Discussion
Neoplasms other than leukaemia or colon cancer
Previous analyses of the mortality among patients with
ankylosing spondylitis treated with X-rays (Court Brown &
Doll, 1957; Smith & Doll, 1982) have shown, in conjunction
with many other studies, that exposure to substantial doses
of ionizing radiation can cause cancer in nearly every organ
in the body. From the earlier follow-up of the spondylitic
population the relative risk for cancers of heavily irradiated
sites was found to have declined more than 20 years after
treatment but the decline was not statistically significant.
The extended follow-up of this cohort has indicated that, for
that group of cancers, and also for the larger group of all
neoplasms other than leukaemia or colon cancer, the period
of increased risk between 5.0 and 24.9 years after irradiation
is followed by a period in which the observed number of
deaths is close to that expected from national rates. For a
smaller group of patients with ankylosing spondylitis, who
were diagnosed during the same period as patients in this
series, but who were not treated with X-rays, the number of
observed deaths from cancer was almost exactly equal to
that expected using national rates (Smith et al., 1977). Thus
the present results suggest that radiation treatment increases
the risk of death from cancer during a period that starts
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about 5 years after exposure, and that the proportionate
increase in risk reaches a maximum about 10 years after the
exposure and then gradually decreases.
This is the first large study to suggest an apparent end to
the effects of exposure to radiation for neoplasms other than
leukaemia and the possibility must be considered that the
findings are spurious. We have already shown that this result
cannot be explained as due to the variation with time in the
types of cancer observed nor to the progressive attenuation
of the older members of the population irradiated relatively
late in life. There is also evidence that patients who survived
and remained in the study for 25 years after the initial
treatment received doses that were no lower than those who
did not. The average estimated total body dose in patients
who remained in the study for less than 25.0 years is 1.87 Gy
(187 rad), while for those who remained in the study for
longer it is 2.04Gy (204 rad). Inadequate ascertainment of
death in the later period of follow-up, resulting in the
erroneous assumption that some patients who had died were
still alive, would also cause the appearance of a spurious
decrease in relative risk with increasing time since treatment.
In order to investigate the possibility that this might have
happened, mortality from all causes of death other than
neoplasms was tabulated by age at observation and calendar-
period (see Table XI). For the total follow-up period, the
relative risk was greatest in individuals in their late twenties
in whom it reached a value of 3.03 and then declined.
However the decline did not continue into old age, and
above the age of 65 the relative risk remained approximately
constant with age, at about 1.24. In the last five calendar
years of follow-up the pattern was similar to that seen in
earlier years, and in the 65-84 age group the relative risk
was 1.29, slightly greater than the value of 1.22 seen in
previous years (Table XI). These findings provide no
evidence of inadequate ascertainment of death in the oldest
age groups in this study.
After the initial course of treatment it seems likely that the
relative risk from neoplasms other than leukaemia or colon
cancer was inflated for about 5 years by tumours that caused
symptoms for which the treatment was given. A similar
pattern might be expected after re-treatment, and following
re-treated patients for a further 18 months only may have
caused a slight underestimation in relative risk. For re-
treated patients, however, the average time between the first
and second treatments was only 2.0 years and only 6 patients
were known to have received a second treatment more than
22 years after the first. The fact that we have not followed
re-treated patients for a full 5 years after their second
treatment cannot therefore have affected the results in the
period more than 22 years after the initial treatment. Thus,
investigation has not revealed any evidence to suggest that
the present findings can be explained in any way other than
by the effect of the irradiation having effectively ceased or,
at least, materially diminished.
It does not necessarily follow that the same pattern of
relative risk with time since exposure will hold for every type
of cancer other than leukaemia, and there is already some
evidence of heterogeneity between the patterns for the
individual sites. A parallel analysis has been carried out of
data from the earlier follow-up of this group of patients with
mortality up to the end of 1978 in Japanese atomic bomb
survivors included in the Life Span Study (LSS) who
received total doses of at least 1 Gy (100 rad) (Darby et al.,
1985). In that analysis, when mortality from a selected group
of solid tumours was compared with mortality from those
same sites in the LSS, the trends in relative risk with time
since exposure were not significantly different, and when
data from the two studies were combined, they were
consistent with a model in which the relative risk did not
vary between about S and at least 30 years following
exposure. The sites selected for this comparison consisted of
pharynx, oesophagus, stomach, pancreas, larynx, lung,
ovaries, skin, and bones (excluding jaw and nose). In the
LSS, however, for neoplasms other than leukaemia or
tumours of the selected sites, the relative risk of mortality
increased with time since exposure, even after adjusting for
age at exposure (Darby et al., 1985), and the overall trend
was significantly different from that seen in the two studies
for the selected sites. Although the numbers of deaths were
too few for the increasing trend in any individual site of
cancer to be significant statistically, cancers of the bladder,
colon, and liver and gall-bladder were the chief contributors
(Darby et al., 1985). Three of the four deaths from multiple
myeloma in the high dose group also occurred more than 25
years after exposure (Radiation Effects Research
Foundation, 1980). In the spondylitis patients multiple
myeloma and cancers of the bladder and liver were among
the few types of cancer for which higher relative risks were
observed more than 25 years after exposure than in the
earlier period (see Table IV).
In a large international study of the incidence of second
cancers in women treated with radiation for cervical cancer,
the relative risk for cancers of sites close to and at inter-
mediate distances from the cervix also increased significantly
with time since treatment, and the increasing trend lasted for
at least 30 years following exposure (Boice et al., 1985).
There were significant increases in relative risk with time
since exposure for a number of individual cancer types
including multiple myeloma and bladder cancer. Thus all
three studies are consistent with a very long term increase in
risk following exposure to radiation for these two diseases.
The remaining sites of cancer for which the relative risk
increased significantly with time since exposure in the cervix
cancer patients were corpus uteri, ovary, and rectum. For the
first two of these sites there is little information in the
spondylitis series as it includes so few women, while for the
rectum there was little evidence of an increase in any time
period. Thus some, at least, of the apparent discrepancies
between the overall patterns of relative risk following
radiation exposure found in three large studies may have
arisen because different groups of cancer types were
examined in each study, and they disappear when the
individual types of cancer are considered. When all three
studies are considered together there are now starting to be
enough data to distinguish different temporal patterns of
radiogenic risk between the different cancer types as well as
for leukaemia.
Age at irradiation did not, in our study, significantly affect
the relative risk of mortality fron neoplasms other than
leukaemia or colon cancer, although during the period 5.0 to
24.9 years since exposure the relative risk did fall pro-
gressively from 1.97 at ages under 25 years to 1.16 at age
over 55 years (Table V). In the LSS a significant decrease in
relative risk with increasing age at exposure occurred, but
this was chiefly due to the high relative risk in those aged
under 15 at exposure, with only a slight trend apparant
among those exposed at older ages (Darby et al., 1985). In
the spondylitic series there were no patients aged under 10 at
exposure, and only 16 in the age range 10-14. At older ages
the two sets of data are in close agreement.
Leukaemia
The extended follow-up of the spondylitis patients has
confirmed the earlier finding that the increase in risk of
mortality from leukaemia reaches its maximum within 5
years of commencement of radiotherapy, and then declines
(Smith & Doll, 1982). This finding is consistent with results
of the LSS, although in that study follow-up did not begin
until October 1950, so no data for this cohort are available
for the first 5 years after the bombings. The earlier spondy-
litis data (Smith & Doll, 1982) were consistent with the
increase in leukaemia having ceased by 18 years after
treatment, but the extended follow-up indicates that the
period of increased risk is longer than this (Table VIII) and
is in agreement with results from the LSS where the relative
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risk more than about 30 years after exposure is still around 2
(Darby et al., 1985). The finding that the relative risk more
than 25.0 years after the first treatment is slightly greater
than in the previous 10 years is unexpected, and could be
due to the play of chance, as the total numbers of deaths
from leukaemia in the periods 15-24 years and more than 25
years after treatment are each only 7. Another possible
explanation might be that some of the leukaemias occurring
in the later period of follow-up were due to treatment of the
spondylitis by drugs as at least one of those that are
commonly used (phenylbutazone) is possibly leukaemogenic
(International Agency for Research on Cancer, 1977). It
should be noted too that the only death certified as due to
leukaemia which on review of the clinical and haemato-
logical evidence appeared not to be due to the disease,
occurred 32 years after first irradiation. The further follow-
up has confirmed the earlier finding that neither the magni-
tude nor the temporal pattern of the leukaemia relative risk
are greatly influenced by the age of the patient when first
treated (Table VII).
It is impossible to draw firm conclusions from the analysis
of observed and expected deaths by type of leukaemia as
recorded on the death certificate, due to the large proportion
of both observed and expected deaths for which the type was
incompletely specified. The results are, however, in accord-
ance with earlier suspicions that the relative risk of acute
myeloid leukaemia following exposure to radiation may be
greater than for other types of leukaemia (Darby, 1985) and
they confirm the belief that chronic lymphatic leukaemia is
much less readily inducible by radiation than the other types
(Court Brown & Doll, 1965; Darby, 1985). It seems likely
that the relative risk of acute myeloid leukaemia increases
with age at exposure whereas there is no such tendency for
this to occur with the other types (Table IX). When
expressed in terms of excess risk there is also a steep rise in
rate with increasing age at exposure for acute myeloid
leukaemia and little or none for other leukaemias. (The
excess risks per 100,000 years at risk in age at treatment
groups: <25 years, 25-34 years, 35-44 years, 45-54 years,
and . 55 years were: -1.5, 4.0, 11.7, 16.5 and 26.4 for
deaths certified as acute myeloid leukaemia, and 2.0, 6.6, 3.7,
12.6 and - 12.7 for all other types of leukaemia apart from
unspecified myeloid leukaemia.) These findings are in accord
with recently published data from the LSS in which the
annual incidence rate of acute myeloid leukaemia among
those with total dose of at least 1 Gy (100 rad) increases
steeply with age at exposure from 2.4 per 100,000 in those
aged under 15 at exposure to 36.8 in those aged over 45,
whereas there was a slight decrease in incidence with
increasing age at exposure for other types of leukaemia
(Darby, 1985; Ichimaru et al., 1981). In the spondylitis
patients 47% of leukaemia deaths were certified as due to
acute myeloid leukaemia, and the preferred diagnosis was
acute myeloid leukaemia in two thirds of those whose case
notes were reviewed. In the Japanese series, in contrast,
among those with total doses of at least 1 Gy (100 rad), a
definite diagnosis of acute myeloid leukaemia was made in
only 36% of leukaemia deaths (with a further 20% in which
the diagnosis is described as other types of acute leukaemia).
The higher proportion of leukaemia deaths due to the acute
myeloid type in the spondylitis series compared with the LSS
accounts for the steeper rise in excess leukaemia risk with
age at exposure in the spondylitics than in the atomic bomb
survivors that has been reported in previous comparisons of
the two studies (Darby et al., 1985; Ichimaru et al., 1978;
Smith & Doll, 1982).
Diseases other than neoplasms
For diseases other than neoplasms, the pattern of relative
risk following treatment is different from that for neoplastic
disease, with an increased level of risk still apparent 30 years
after first treatment (Table III). The high mortality is not
confined to those diseases that have long been recognized
clinically to be associated with spondylitis, but was observed
also for all other groups of diseases, though to a lesser
extent. A similar excess has, however, also been observed in
unirradiated patients (Radford et al., 1977) and should not
be attributed to the treatment. This conclusion is strength-
ened by our finding that when the data were subdivided by
age at observation the relative risk rose from 1.50 for
subjects under 25 years of age to over 3 among those aged
25-29 and remained at above 2 until age 40-44 before
declining (Table XI). Since the age at clinical onset of
spondylitis is, in the vast majority of cases, between 15 and
35 (Kelsey, 1982) the ages at which the relative risk was
highest lag the ages at which onset is most likely to occur by
about 10 years. In contrast, when the data were subdivided
by time since first treatment, the relative risk tended to
decline progressively from the time of first treatment and
never exceeded 2 (Table III). The increased risk for non-
neoplastic disease is, therefore, more closely associated with
the patient's age than with the time since first radiotherapy
treatment.
The relative risk for diseases other than neoplasms was
higher in women than in men (Table II), but only 16.5% of
this irradiated series were women, compared with 37% of
the group of unirradiated spondylitics diagnosed during the
same period (Smith et al., 1977). These differences may
reflect a reluctance to recommend radiation treatment for
women of childbearing age even before 1955, so that even
though the disease is generally milder in women than in men
(Kelsey, 1982; Radford et al., 1977), it is worse in the
irradiated series because of the selection of more severe cases
for treatment.
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